Clinical Trial Update: Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency [Phase 3]

View source ↗

Summary

Phase 3 clinical trial in autosomal dominant polycystic kidney disease with moderate to severe renal insufficiency has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Snippet

Sponsor: Mario Negri Institute for Pharmacological Research | Conditions: Autosomal Dominant Polycystic Kidney Disease | Phase 3 | Status: COMPLETED